



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : MR. R. VANLALRUATA
ASSISTANT DIRECTOR (F & D)
OFFICE OF CHIEF MEDICAL OFFICER,
AIZAWL, MIZORAM, PIN:-796017
- Serial No. and date of Inspector's memorandum : 13/IPA-AZL 'E'/II-2025 Date 16/4/2025
- Number of Sample : Nil
- Date of receipt : 22-APR-2025
- Names of drugs purporting to be contained in the sample : Cetirizine Hydrochloride Tablet I.P. 10 mg (CETNET)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By.	Mfg. By
LSD/GUW/2025-26/0274	GUW/LS/2025-26/285	ATN-181	07/2024 06/2026	NA	Amree Pharmaceuticals Plot No:1, Street 10, Kaithan Road, Karnal-132001

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] Specimen impression of the seal
received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 05-May-2025 To 14-May-2025

COMPOSITION : Each uncoated tablet contains:
Cetirizine Hydrochloride IP 10 mg
Protocol Applied: I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, elongated, uncoated tablet, having a dosage line on one side in blister pack.	NA
2	Identification	Gives positive test for Cetirizine Hydrochloride.	NA
3	Average weight	0.1534 gm.	NA
4	Dissolution	Complies (Release of all six units were found above 'Q' 75+5%).	NLT 75 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cetirizine Hydrochloride	10.75 mg/Tablet	10 mg/Tablet	107.5	90 % to 110 %	I.P. 2022

In the opinion of the under signed the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules thereunder for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 27-MAY-2025



GOVERNMENT ANALYST

Dilip Kr. Sarkar

Government Analyst

R.D.T.L., Guwahati-22

-----END OF REPORT-----

